La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Instil Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Instil Bio..

Instil Bio (NASDAQ:TIL) Azioni, Catena delle Opzioni

INSTIL BIO INC

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Instil Bio Inc

Till Capital Corp

Interface Inc

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator ("VEON" or the "Company"), today held its Annual General Meeting (AGM) in New York City at Nasdaq Stock Market, where the Company is listed. With the AGM, the Company's shareholders approved the recommended slate of seven directors as VEON's incoming Board of Directors (the "Board"), re-electing the seven directors who served on VEON's Board in the previous term.
VEON welcomes back its founder Augie K Fabela II, Andrei Gusev, Rt. Hon. Sir Brandon Lewis CBE, Duncan Perry, 70th U.S. Secretary of State Michael R. Pompeo, Michiel Soeting and VEON Group CEO Kaan Terzioglu to the Board. Following the AGM, the new Board held its inaugural meeting, and re-elected VEON's Founder Augie K Fabela II as the Chairman for a second term.

News

Management

VEON

VEON Board Re-Elects Founder Augie Fabela II As Chairman For Second Term

Macro Economic Events

Global

Economics

President Trump Asked If China Tariff Can Be Lowered, Says "Could Be", I Think We're Going To Have A Very Good Relationship With China; Would Like To See China Open; Think We'll Have Good Weekend With China; Might See Xi After Weekend Talks

Stephens &amp; Co. analyst Kyle Joseph maintains Propel Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PRL#TSX">PRL</a>) with a Overweight and raises the price target from C$32 to C$36.

Price Target

Analyst Ratings

TSX:PRL

Stephens & Co. Maintains Overweight on Propel Holdings, Raises Price Target to C$36

Canaccord Genuity analyst George Gianarikas maintains Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>) with a Buy and lowers the price target from $1 to $0.75.

Canaccord Genuity Maintains Buy on Wallbox, Lowers Price Target to $0.75

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and raises the price target from $17 to $20.

STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Raises Price Target to $20

WIIM

PAYC

Paycom Software shares are trading higher after the company reported better-than-expected Q1 earnings and sales.

Tempus AI shares are trading higher after the company reported better-than-expected Q1 results and raised its FY25 sales guidance.

<a href="https://www.youtube.com/watch?v=WElDJC0Q_kQ">https://www.youtube.com/watch?v=WElDJC0Q_kQ</a>
&nbsp;

President Trump Says Intend To Make Deal With Europe; Will Be Dealing With Europe

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and raises the price target from $19 to $22.

PINC

Canaccord Genuity Maintains Hold on Premier, Raises Price Target to $22

Goldman Sachs analyst Mike Burton maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Neutral and lowers the price target from $77 to $69.

Goldman Sachs Maintains Neutral on Zillow Gr, Lowers Price Target to $69

Contracts

Politics

General

UK Government Says U.S. Tariffs On Automotives Immediately Slashed From 27.5%, With Steel And Aluminum Reduced To 0%; U.S. Trade Deal Gives Unprecedented Market Access For British Farmers With Protections On Food Standards Maintained; The Digital Services Tax Remains Unchanged As Part Of U.S. Trade Deal; UK And U.S. Have Agreed To Work On A Digital Trade Deal That Will Strip Back Paperwork For British Firms Trying To Export To The U.S.

Canaccord Genuity analyst David Hynes maintains ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) with a Hold and lowers the price target from $9 to $5.

ONTF

Canaccord Genuity Maintains Hold on ON24, Lowers Price Target to $5

Stephens &amp; Co. analyst Trey Grooms maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Equal-Weight and lowers the price target from $340 to $320.

Stephens & Co. Maintains Equal-Weight on TopBuild, Lowers Price Target to $320

Life Time Group Holdings shares are trading lower following Q1 reported financial results.

INSM

Insmed shares are trading lower after the company reported worse-than-expected Q1 earnings and reaffirmed full-year guidance below estimates.

Six Flags Entertainment shares are trading lower after the company reported worse-than-expected Q1 sales results.

Houlihan Lokey shares are trading higher after the company reported better-than-expected Q4 financial results.

Canaccord Genuity analyst Brian McNamara maintains Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) with a Buy and lowers the price target from $200 to $186.

MIDD

Canaccord Genuity Maintains Buy on Middleby, Lowers Price Target to $186

Goldman Sachs analyst Bruno Montanari maintains Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Buy and raises the price target from $30 to $33.

XMTR

Goldman Sachs Maintains Buy on Xometry, Raises Price Target to $33

DOCS

Amdocs shares are trading higher after the company reported better-than-expected Q2 earnings and sales.

Earnings

Press Releases

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Comments

Instil Bio

Instil Bio (TIL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO